Effect of Pregabalin on Cardiovascular Responses to Exercise and Postexercise Pain and Fatigue in Fibromyalgia: A Randomized, Double-Blind, Crossover Pilot Study.
Effect of Pregabalin on Cardiovascular Responses to Exercise and Postexercise Pain and Fatigue in Fibromyalgia: A Randomized, Double-Blind, Crossover Pilot Study.
复制标题
普瑞巴林对纤维肌痛患者运动和运动后疼痛和疲劳的心血管反应的影响：一项随机、双盲、交叉试点研究。
DOI：
10.1155/2015/136409
复制
发表时间：
2015
影响因子：
--
通讯作者：
Light,AlanR
中科院分区：
文献类型：
--
作者：
White,AndreaT;Light,KathleenC;Bateman,Lucinda;Hughen,RonaldW;Vanhaitsma,TimothyA;Light,AlanR
普瑞巴林是一种被批准用于治疗纤维肌痛（FM）的药物，已被证明可降低交感神经系统（SNS）活性并抑制交感神经维持性疼痛，但其对运动反应的影响尚未得到证实。采用随机双盲交叉设计，我们在19名FM患者中评估了5周普瑞巴林（与安慰剂相比）对中度运动的急性心血管反应和主观反应的影响。比较了普瑞巴林组与安慰剂组以及18名健康对照组的血压（BP）、心率（HR）、运动期间的感觉劳累（RPE）评分以及运动前、运动中和运动后48小时的疼痛、身体疲劳和精神疲劳评分。在安慰剂组，FM患者的运动RPE和BP显著高于对照组（p< 0.04）。普瑞巴林应答者（n= 12，根据患者满意度和症状变化定义）与安慰剂相比，普瑞巴林的运动BP、HR和RPE显著降低（p< 0.03），与对照组相比不再有差异（p> 0.26）。无应答者（n= 7）的心血管反应未被普瑞巴林改变。普瑞巴林改善了应答者的疲劳和疼痛评分（p< 0.04），但对无应答者的疼痛和疲劳有负面影响。这些初步研究结果表明，普瑞巴林可能使许多FM患者对运动的心血管和主观反应正常化。
Pregabalin, an approved treatment for fibromyalgia (FM), has been shown to decrease sympathetic nervous system (SNS) activity and inhibit sympathetically maintained pain, but its effects on exercise responses have not been reported.Methods. Using a randomized double‐blind crossover design, we assessed the effect of 5 weeks of pregabalin (versus placebo) on acute cardiovascular and subjective responses to moderate exercise in 19 FM patients. Blood pressure (BP), heart rate (HR), and ratings of perceived exertion (RPE) during exercise and ratings of pain, physical fatigue, and mental fatigue before, during, and for 48 hours after exercise were compared in patients on pregabalin versus placebo and also versus 18 healthy controls.Results. On placebo, exercise RPE and BP were significantly higher in FM patients than controls (p< 0.04). Pregabalin responders (n= 12, defined by patient satisfaction and symptom changes) had significantly lower exercise BP, HR, and RPE on pregabalin versus placebo (p< 0.03) and no longer differed from controls (p> 0.26). Cardiovascular responses of nonresponders (n= 7) were not altered by pregabalin. In responders, pregabalin improved ratings of fatigue and pain (p< 0.04), but negative effects on pain and fatigue were seen in nonresponders.Conclusions. These preliminary findings suggest that pregabalin may normalize cardiovascular and subjective responses to exercise in many FM patients.